Kardigan Inc. shares surged 27% in their trading debut, making the heart-health focused biotech one of the most notable first-day gainers in recent memory. The company raised $400 million through its IPO, underscoring robust demand for cardiovascular disease treatments.
The strong opening signals renewed investor appetite for biotech IPOs, a sector that had seen a sluggish recovery following the market downturn. Kardigan's focus on heart health, a massive and growing therapeutic area, likely attracted both specialist healthcare funds and generalist investors.
According to Bloomberg, the company priced its offering at the midpoint of its expected range, raising the full $400 million target. The stock opened well above the IPO price and maintained its momentum through the session.
For Kardigan, the proceeds will fund clinical trials and pipeline expansion. The warm reception could encourage other biotechs to pursue public listings, potentially opening a new window for capital raising in the sector.
One source reported the stock edged up "nearly 2%," but the consensus from Bloomberg indicates the closing surge was far more dramatic, around 27%.